AnGes, Inc. Share Price

Equities

4563

JP3127700007

Biotechnology & Medical Research

Market Closed - Japan Exchange 11:30:00 26/04/2024 am IST 5-day change 1st Jan Change
49 JPY 0.00% Intraday chart for AnGes, Inc. -2.00% -31.94%

Financials

Sales 2022 67M 423K 35.28M Sales 2023 152M 960K 80.03M Capitalization 14.23B 89.83M 7.49B
Net income 2022 -14.71B -92.89M -7.75B Net income 2023 -7.44B -46.95M -3.92B EV / Sales 2022 165 x
Net cash position 2022 9.88B 62.38M 5.2B Net cash position 2023 3.8B 23.98M 2B EV / Sales 2023 68.6 x
P/E ratio 2022
-1.29 x
P/E ratio 2023
-1.83 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 96.87%
More Fundamentals * Assessed data
Dynamic Chart
1 week-2.00%
Current month-25.76%
1 month-26.87%
3 months-32.88%
6 months-43.02%
Current year-31.94%
More quotes
1 week
49.00
Extreme 49
51.00
1 month
49.00
Extreme 49
67.00
Current year
49.00
Extreme 49
92.00
1 year
49.00
Extreme 49
143.00
3 years
49.00
Extreme 49
1 060.00
5 years
49.00
Extreme 49
2 492.00
10 years
49.00
Extreme 49
2 492.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 54 01/12/01
President 73 01/01/01
Chief Tech/Sci/R&D Officer 67 01/19/01
Members of the board TitleAgeSince
President 73 01/01/01
Director/Board Member 73 29/18/29
Director/Board Member 73 01/12/01
More insiders
Date Price Change Volume
26/24/26 49 0.00% 530,600
25/24/25 49 0.00% 847,400
24/24/24 49 0.00% 515,400
23/24/23 49 -2.00% 1,598,600
22/24/22 50 0.00% 1,456,800

Delayed Quote Japan Exchange, April 26, 2024 at 11:30 am IST

More quotes
AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
Calendar
More about the company